[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Gail Schulze Biography and Net Worth

Director of Cerus

Ms. Schulze has served as a member of our Board since 2007. From May 2008 until June 2012, she was the Chief Executive Officer and Chairman of the board of directors of Zosano Pharma, a biopharmaceutical company. From May 2006 to March 2007, she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a then global biopharmaceutical organization. Prior to joining YM Biosciences in 2006, she was President, Chief Executive Officer and a director of Eximias Pharmaceutical Corporation, then a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004, Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, then a fully independent biologics subsidiary of Aventis, and from 1997 to 2001, she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997, she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995, Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards. She received a B.A. with highest honors in psychobiology from the University of California, Santa Cruz, studied neurophysiology at the University of Wisconsin and received her M.B.A. from the Stanford Graduate School of Business.

What is Gail Schulze's net worth?: The estimated net worth of Gail Schulze is at least $107,315.96 as of December 14th, 2020. Ms. Schulze owns 62,393 shares of Cerus stock worth more than $107,316 as of November 15th. This net worth approximation does not reflect any other assets that Ms. Schulze may own. Learn More about Gail Schulze's net worth.
How do I contact Gail Schulze?: The corporate mailing address for Ms. Schulze and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Gail Schulze's contact information.
Has Gail Schulze been buying or selling shares of Cerus?: Gail Schulze has not been actively trading shares of Cerus within the last three months. Most recently, Gail Schulze sold 25,000 shares of the business's stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $7.54, for a transaction totalling $188,500.00. Learn More on Gail Schulze's trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, Cerus insiders bought shares 3 times. They purchased a total of 15,000 shares worth more than $25,875.00. In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 227,506 shares worth more than $488,803.79. The most recent insider tranaction occured on September, 3rd when CFO Kevin Dennis Green sold 28,385 shares worth more than $61,879.30. Insiders at Cerus own 3.4% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 9/3/2024.

Gail Schulze Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/9/2021	Sell	25,000	$7.54	$188,500.00
12/14/2020	Sell	62,393	$7.32	$456,716.76	62,393
12/4/2019	Sell	15,000	$4.19	$62,850.00	40,986
6/8/2018	Sell	52,500	$6.65	$349,125.00	40,986

Gail Schulze Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $1.72

$1.69

$1.82

50 Day Range

MA: $1.79

$1.52

$2.07

2 Week Range

Now: $1.72

$1.38

$2.59

Volume

1,494,732 shs

Average Volume

1,298,101 shs

Market Capitalization

$319.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2